Core Insights - CVRx, Inc. announced the schedule for scientific presentations on Barostim therapy at the Technology and Heart Failure Therapeutics 2026 meeting, highlighting its focus on innovative neuromodulation solutions for cardiovascular diseases [1][6] Group 1: Scientific Presentations - The presentations will include late-breaking clinical data, oral sessions, and posters that cover real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements, and changes in advanced hemodynamics [2] - Dr. Dmitry Yaranov will present data from the REBALANCE Registry, which evaluates the safety and benefits of Barostim therapy in a commercial setting, focusing on six-month outcomes from over 400 patients [3] Group 2: Clinical Trials and Studies - CVRx will host a satellite program featuring updates on the REBALANCE Registry, the BREATHE-HF trial, and the BENEFIT-HF trial, with the latter being a landmark randomized study supported by CMS Category B IDE coverage [4] - The BENEFIT-HF trial aims to evaluate the impact of Barostim in a broader heart failure population, with a primary endpoint of all-cause mortality and heart failure decompensation events, and enrollment is expected to begin in the first half of 2026 [4] Group 3: Company Overview - CVRx is a commercial-stage medical device company that has developed Barostim, the first FDA-approved neuromodulation technology for improving heart failure symptoms [6] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, designed to restore balance to the autonomic nervous system and reduce heart failure symptoms [6]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $16 million, representing a growth of 4% year-over-year, while full year revenue reached $56.7 million, reflecting a 10% increase [3][17] - Gross profit for the fourth quarter was $13.8 million, an increase of 8%, with gross margin rising to 86% from 83% a year ago [19] - Net loss for the fourth quarter was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in the same quarter of the previous year [22] Business Line Data and Key Metrics Changes - Revenue generated in the U.S. was $14.9 million, an increase of 4%, with revenue units totaling 478, up from 460 in the prior year [17] - Revenue in Europe was $1.1 million, a 10% increase, with total revenue units rising to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only less than 1% penetration [6] - The ongoing BENEFIT-HF trial could potentially triple the addressable market to approximately $30 billion if successful [13] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [7] - The transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, which is a significant milestone for the company [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute the program-focused selling approach as they gain experience [8] - The initiation of the BENEFIT-HF trial is seen as a significant development that will enhance visibility and credibility in the heart failure community [25] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and provide access to additional capital [15][23] - The company expects total revenue for 2026 to be between $63 million and $67 million, with a gross margin between 84% and 86% [23] Q&A Session Summary Question: Can you talk about the initial sites for the BENEFIT-HF trial? - The trial will involve about 150 centers in the U.S. and some in Germany, with a mix of existing and new commercial sites [28] Question: How should we expect the growth of active accounts to trend through 2026? - The company expects to add around 3 active territories on a quarterly basis, leading to high single-digit account additions on a net basis each quarter in 2026 [31] Question: Do you see any scenario where the trial can be a tailwind for the core business? - Management believes there will be a goodwill effect and credibility boost from the trial, positively impacting the core business [35] Question: Can you share any anecdotal examples of how the Category I code has helped lower barriers to treatment? - Early signs show that payers who previously rejected prior authorizations are beginning to approve them, indicating positive progress [38] Question: What gives you confidence in the revenue guidance for 2026? - The company has seen sequential growth from Q1 to Q4 in 2025 and expects to return to growth after a seasonal dip from Q4 to Q1 [41] Question: Can you discuss the path to profitability? - The company has sufficient cash reserves and access to additional capital, with a focus on generating leverage through sales productivity [75]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $16 million, representing a 4% increase year-over-year, while full year revenue reached $56.7 million, reflecting a 10% growth [3][17] - Gross profit for the fourth quarter was $13.8 million, an increase of 8%, with gross margin rising to 86% from 83% a year ago [19] - Net loss for the fourth quarter was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in the prior year [22] Business Line Data and Key Metrics Changes - Revenue generated in the U.S. was $14.9 million, a 4% increase, with revenue units totaling 478, up from 460 in the prior year [17] - Revenue in Europe was $1.1 million, a 10% increase, with total revenue units rising to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only less than 1% penetration [6] - The potential market could triple to approximately $30 billion if the BENEFIT-HF trial is successful, expanding the addressable patient population from 339,000 to over 980,000 [13] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [7] - The transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, effective January 1, 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute the program-focused selling approach as they gain experience [8] - The initiation of the BENEFIT-HF trial is seen as a significant development that will enhance visibility and credibility in the heart failure community [25] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and provide access to additional capital [15][23] - The company expects total revenue for 2026 to be between $63 million and $67 million, with a gross margin between 84% and 86% [23][24] Q&A Session Summary Question: Can you talk about the initial sites for the BENEFIT-HF trial? - The trial will involve about 150 centers in the U.S. and some in Germany, with a mix of existing and new commercial sites [28] Question: How should we expect the growth of active accounts to trend through 2026? - The company expects to add around three active territories quarterly, leading to high single-digit account additions on a net basis each quarter in 2026 [31] Question: Do you see any scenario where the trial can be a tailwind for the core business? - Management believes there will be a goodwill effect and credibility boost from the trial, positively impacting the core business [35] Question: Can you share any anecdotal examples of how the Category I code has helped lower barriers to treatment? - Early signs show that payers who previously rejected prior authorizations are beginning to approve them, indicating positive progress [38] Question: What gives you confidence in the revenue guidance for 2026? - The company has seen sequential growth from Q1 to Q4 in 2025 and expects to return to growth after a seasonal dip from Q4 to Q1 [41] Question: How do you expect to manage the business to profitability over the medium term? - The company has sufficient cash reserves and plans to generate leverage by increasing sales productivity while managing expenses [75]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $16 million, a 4% increase year-over-year, while full-year revenue reached $56.7 million, reflecting a 10% growth [3][17] - Gross profit for Q4 was $13.8 million, an 8% increase, with gross margin rising to 86% from 83% a year ago [19] - Net loss for Q4 was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in Q4 2024 [21] Business Line Data and Key Metrics Changes - U.S. revenue was $14.9 million in Q4 2025, a 4% increase, with revenue units totaling 478, up from 460 in the prior year [17] - European revenue increased to $1.1 million, a 10% rise, with revenue units growing to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only 1% penetration, indicating significant growth potential [5] - The initiation of the BENEFIT-HF trial could expand the addressable market to approximately $30 billion if successful [12] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [6] - Transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, effective January 1, 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute and drive growth, despite a natural ramp-up period for new sales representatives [6][15] - The company anticipates total revenue for 2026 to be between $63 million and $67 million, with a gross margin of 84% to 86% [23] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and increase access to additional capital [14][22] - A new Chief Human Resources Officer was appointed, indicating ongoing organizational development [16] Q&A Session Summary Question: On the BENEFIT-HF trial strategy and revenue generation - Management indicated that the trial will involve a mix of existing and new commercial sites, with expected revenue from approximately 1,600 to 1,700 devices sold during the trial [26][28] Question: Growth of active accounts in Q4 - Management noted that while there was a net addition of accounts, the focus remains on deepening existing relationships, with expectations of adding around three active territories quarterly in 2026 [30][31] Question: Impact of the Category I code on treatment barriers - Management reported positive early signs of improved prior authorization approvals and expects this trend to continue as the transition progresses [36][39] Question: Path to profitability and cash management - The company has sufficient cash reserves and access to additional capital, with a focus on driving sales productivity to achieve profitability [72][74]

Core Insights - CVRx, Inc. has initiated the BENEFIT-HF clinical trial, a significant randomized study aimed at evaluating the impact of Barostim in a larger heart failure population [1][3] - Barostim is an implantable device that enhances baroreflex signaling to improve heart failure symptoms and has been commercially available since FDA approval in 2019 [2] - The BENEFIT-HF trial is expected to be one of the largest therapeutic cardiac device trials, randomizing 2,500 patients with a primary endpoint focused on all-cause mortality and heart failure decompensation events [3] Company Developments - If successful, the BENEFIT-HF trial could potentially triple the indicated patient population for Barostim, broadening access to this heart failure management approach [4] - Analyst commentary suggests that the trial's success could significantly increase the company's total addressable market (TAM) and attract more attention within the cardiology community [5] - The trial's design includes CMS coverage, which is seen as a key milestone that could unlock additional revenue potential, with an estimated $50 million in top-line revenue from Barostim therapy for approximately 1,650 patients [5] Market Reaction - Following the announcement, CVRx shares experienced a notable increase of 15.93%, reaching $7.60 [6]

Core Insights - CVRx, Inc. has initiated the BENEFIT-HF clinical trial, which is expected to be one of the largest therapeutic cardiac device trials for heart failure, supported by CMS Category B IDE coverage [1][4][5] - The trial aims to evaluate the Barostim™ device in a significantly expanded heart failure population, potentially tripling the indicated patient population for the device [3][5] Company Overview - CVRx, Inc. is a medical device company focused on developing innovative neuromodulation solutions for cardiovascular diseases [6] - Barostim™ is the first FDA-approved medical technology that uses neuromodulation to alleviate heart failure symptoms, receiving FDA Breakthrough Device designation in 2019 [2][6] Clinical Trial Details - The BENEFIT-HF trial will randomize 2,500 patients across approximately 150 centers in the U.S. and Germany, with the primary endpoint being a composite of all-cause mortality and heart failure decompensation events [3] - Enrollment for the trial is expected to begin in the first half of 2026 [3] Patient Population Criteria - The trial will include patients who remain symptomatic after receiving optimized guideline-directed medical and device therapies, have a left ventricular ejection fraction (LVEF) <50%, and NT-proBNP levels <5,000 pg/mL [7]

CVRx Conference Call Summary Company Overview - **Company**: CVRx - **Industry**: Medical Technology (MedTech) - **Product**: Barostim, an autonomic neuromodulation therapy for heart failure treatment - **Market Size**: $10.5 billion prevalence-based market for heart failure treatment [3][6] Key Points and Arguments Heart Failure Market Dynamics - Heart failure affects approximately 6.7 million Americans, leading to over 1 million hospital discharges and emergency room visits annually, with costs projected to reach nearly $70 billion per year by the end of the decade [3][4] - Current treatment involves a combination of four drugs (quad therapy), which only 1% of patients reach optimal dosages, and over 40% discontinue within the first year [5][6] - Patients prioritize quality of life over longevity, indicating a significant unmet need for effective therapies that improve daily living [6][12] Barostim Therapy - Barostim targets the neurohormonal pathway, addressing the root cause of heart failure by restoring signaling to the brain, thus reducing the toxic effects of neurohormones [9][10] - The therapy has shown a 68% improvement in functional status and a 94% response rate in clinical outcomes [11][12] - The BeAT-HF trial demonstrated significant improvements in quality of life and exercise capacity, with a positive signal in all-cause mortality [12] Commercial Strategy - CVRx aims to establish Barostim as the standard of care through improved salesforce productivity, deep adoption in targeted centers, and addressing barriers to therapy adoption [13][21] - The company has transformed its salesforce, focusing on mentoring and training to enhance productivity [13][15] - Building networks of aligned stakeholders, including clinical and financial champions, is crucial for deeper adoption [16][17] Barriers to Adoption - Key barriers include awareness, evidence, and patient access [21][30] - The implementation of Category 1 codes has improved reimbursement processes, increasing confidence among physicians regarding patient coverage [30][31] - The company has seen a 46% approval rate for Medicare Advantage within 30 days, a significant improvement from previous years [32][46] Financial Performance and Projections - Q4 2025 worldwide revenue was approximately $15.9-$16.1 million, with a total for the year of $56.5-$56.7 million, reflecting an 11% growth rate [33] - For 2026, projected revenue is between $63 million and $67 million, with gross margins of 84%-86% [33] - The company anticipates a cash burn of $35-$40 million for 2026, with a focus on achieving cash flow break-even through increased sales productivity [38][41] Future Opportunities - The BenefitHF trial, a landmark randomized controlled trial, aims to expand the indication for Barostim, potentially tripling the total addressable market from $10 billion to over $30 billion [25][27] - The trial will enroll 2,500 patients and is expected to begin later this year, pending CMS approval [26][29] Conclusion - CVRx is positioned to significantly impact the treatment of heart failure, addressing a critical unmet need and improving the quality of life for many patients [34] - The company is focused on executing its strategy to drive adoption and achieve sustainable growth in the coming years [35][49]

Market Opportunity & Prevalence - The prevalence-based market opportunity for Barostim is estimated at $10.5 billion in the U S HFrEF market[8, 9] - Heart failure affects nearly 6.7 million adults in the U S [10] - The company is less than 1% penetrated into its addressable market[36] Clinical Efficacy & Safety - Barostim implantation has a 97% freedom from major complications rate[54, 56] - Barostim shows a clinically relevant 94% response rate[58] - Real-world evidence demonstrates an 85% relative reduction in hospital visits per year post-Barostim implant (average 1 92 years) compared to pre-implant (12 months)[67, 68] Financial Performance & Guidance - Preliminary Q4 2025 worldwide revenue is $15 9–$16 1 million[104] - Preliminary 2025 worldwide revenue is $56 5–$56 7 million, with a gross margin of 84%-86%[104, 105] - The company expects total revenue between $63 0 million and $67 0 million for the full year of 2026[108] Growth Strategy - The company's strategy focuses on improving salesforce productivity, driving deep adoption in targeted centers, and addressing barriers to adoption[70, 71] - The company is focusing therapy awareness efforts on the clinicians and patients that surround targeted centers[84] - The company has received IDE approval for BENEFIT-HF, a potential landmark randomized controlled trial (RCT) in HF, with a trial size of 2,500 patients[94, 95]

Core Insights - CVRx, Inc. has transitioned to Category I Current Procedural Terminology (CPT) codes for its Barostim device, effective January 1, 2026, replacing the previous Category III codes, which is expected to enhance adoption, coverage, and reimbursement for the therapy [1][2][3] Company Overview - CVRx, Inc. is a commercial-stage medical device company that specializes in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases [3] - The Barostim device is the first FDA-approved medical technology that utilizes neuromodulation to alleviate symptoms in heart failure patients [3] - Barostim functions by delivering electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3] Regulatory and Market Impact - The new Category I CPT codes are anticipated to provide more predictable and consistent reimbursement for healthcare professionals and patients using Barostim therapy [3] - The Barostim device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as being compliant with EU Medical Device Regulation and holding CE Mark approval for heart failure and resistant hypertension in the European Economic Area [3]